General description
RET or ret proto-oncogene is a member of the cadherin superfamily that encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. RET can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in the RET gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. RET signaling pathway, by regulating the development of both the nervous and lymphoid system in the gut, plays a key role in the molecular mechanisms that orchestrate intestine organogenesis.
Physical form
Supplied in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM glutathione, 0.1 mM EDTA, 0.25 mM DTT, 0.1 mM PMSF, 25% glycerol.
Preparation Note
After opening, aliquot into smaller quantities and store at -70 °C. Avoid repeating handling and multiple freeze/thaw cycles.
Legal Information
PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany
| recombinant | expressed in baculovirus infected Sf9 cells |
| product line | PRECISIO® |
| assay | ≥70% (SDS-PAGE) |
| form | buffered aqueous glycerol solution |
| specific activity | 364-546 nmol/min·mg |
| mol wt | ~74 kDa |
| NCBI accession no. | NM_020630 |
| shipped in | dry ice |
| storage temp. | −70°C |
| Gene Information | human ... RET(5979) |
